IceCure Medical Ltd
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- IceCure Medical Ltd (Nasdaq: ICCM), a commercial-stage medical device company founded in 2006 and headquartered in Caesarea, Israel, researches, develops, and markets liquid nitrogen-based cryoablation systems, disposables, and technologies for the minimally invasive treatment of benign and malignant tumors in women's health and interventional oncology. The company offers the ProSense system, a single-probe cryoablation platform using liquid nitrogen to generate ultra-cold temperatures for creating large lethal zones in tumors such as malignant breast tumors (FDA-cleared in October 2025 for patients aged 70+ with low-risk tumors ≤1.5 cm treated with endocrine therapy), kidney, lung, liver, and bone cancers; the IceSense3 system for ablation across urology (prostate cancer, BPH), oncology, dermatology (skin cancers, warts), gynecology, general surgery (breast fibroadenomas), thoracic surgery, ENT, proctology (hemorrhoids, pilonidal cysts), and palliative care; and developmental-stage systems including XSense (single-probe) and MultiSense (multi-probe for larger tumors). IceCure operates in the United States, Europe (including recent regulatory approval for ProSense in Switzerland covering breast, lung, liver, and kidney indications), Japan (via partner Terumo Corporation, with regulatory submission planned for H1 2026), Israel, India, China, and other international markets, targeting physicians in interventional radiology, oncology, urology, and surgery for office-based and CT-guided procedures. Recent developments include FDA marketing authorization for ProSense in early-stage low-risk breast cancer in October 2025, promotion of Shay Levav to Chief Operating Officer in November 2025 to support U.S. commercial scaling to 30 sites, closure of a $10 million over-subscribed rights offering in August 2025, submission of next-generation XSense to Israeli regulators, positive interim ICESECRET kidney study results (88.7% recurrence-free rate for tumors ≤3 cm presented in March 2025), and ongoing post-market study protocols with the FDA.
Company News
IceCure Signs Exclusive Distribution Agreement for ProSense® Cryoablation Systems in the Netherlands
West Cancer Center Receives IRB Approval to Commence IceCure's ChoICE Study for Breast Cancer Cryoablation
IceCure Highlights Two New Peer-Reviewed Publications Supporting Cryoablation in Breast Cancer Treatment De-Escalation
IceCure Medical Ltd (ICCM) Q2 2026 Earnings Call Transcript
IceCure Reports its Financial Results for the First Half of 2026 with 45% Revenue Growth Year-Over-Year
IceCure Medical Adds Adventist Health as U.S. Clinical Site for its Post-Marketing "ChoICE" Study for Low-Risk Breast Cancer Cryoablation Treatment
IceCure Medical to Report First Half 2026 Financial and Operating Results on August 12, 2026
IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance of ProSense®
IceCure Medical Kicks Off its Post-Marketing "ChoICE" Study for the Low-Risk Breast Cancer Treatment at First U.S Clinical Site
IceCure Expands U.S. Commercial Team to Meet Surging Demand for ProSense® Cryoablation
IceCure Highlights Expanding Commercial Adoption of ProSense™ Cryoablation in Brazil Following FDA Clearance for Breast Cancer
IceCure Regains Compliance with Nasdaq Minimum Bid Price Requirement
IceCure Highlights New Peer-Reviewed Journal Article in Leading Surgery Journal, Demonstrating Cryoablation's Advantages Over Radiofrequency Ablation for Early-Stage Breast Cancer
IceCure Announces Pricing of $5.5 Million Private Placement Priced At a Premium to the Market Price with a Single Healthcare Focused Institutional Investor
IceCure Stock Surges After 70% ProSense Install Increase
IceCure Reports 70% Growth in Active U.S. Commercial Install Base for Breast Cancer Cryoablation Following FDA Clearance
IceCure Medical Announces 1-for-30 Reverse Share Split to Support Nasdaq Compliance
IceCure's ProSense® Reports Nearly 90% Recurrence-Free Rate for Cryoablation of Kidney Cancer: Data Presented at ECIO 2026 and First-Ever Breast Cryoablation Master Class Overbooked
IceCure Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement
IceCure Medical Ltd (ICCM) Q1 2026 Earnings Call Transcript